10 ~~42.~~ The modified release tablet of claim ~~33~~ 1 wherein the C_{max}, AUC_{inf} and AUC_{0-12} are approximately proportional to dosage strength.

B2

11 ~~43.~~ The modified release tablet of claim ~~33~~ 1 or ~~39~~ 7 wherein the ratio of said first quantity of guaifenesin to said second quantity of guaifenesin is about 1:1 to about 1:5.

12 ~~44.~~ The modified release tablet of claim ~~33~~ 1 or ~~39~~ 7 wherein the ratio of said first quantity of guaifenesin to said quantity of second quantity of guaifenesin is about 1:5.

B3

14 ~~46.~~ The modified release tablet of claim ~~41~~ 9 wherein the C_{max} of said tablet is at least 1900 μg/mL and said tablet has an AUC_{inf} of at least 7000 hr*μg/mL.

B4

16 ~~48.~~ The modified release tablet of claim ~~40~~ 8 wherein the C_{max} of said tablet is at least 1000 μg/mL and said tablet has an AUC_{inf} of at least 3500 hr*μg/mL.

[

Please add the following new claims 56-88 as follows:

24 ~~56.~~ A modified release product having two portions, wherein a first portion comprises a first quantity of guaifenesin in an immediate release form which becomes fully bioavailable in the subject's stomach and a second portion comprises a second quantity of guaifenesin in a sustained release form wherein the ratio of said first quantity to said second quantity provides a C_{max} in a human subject equivalent to the C_{max} obtained when the first of three doses of a standard immediate release formulation having one third the amount of guaifenesin is dosed every four hours over a 12 hour period and wherein said product also provides therapeutically effective bioavailability for at least twelve hours after a single dose in a human subject according to serum analysis.

B5

25 ~~57.~~ The modified release product of claim ~~56~~ 24 wherein the total quantity of guaifenesin is from about 600 mg to about 1200 mg.

26 ~~58.~~ The modified release product of claim ~~56~~ 24 wherein the total quantity of guaifenesin is 600 mg.

27 ~~59.~~ The modified release product of claim ~~56~~ 24 wherein the total quantity of guaifenesin is 1200 mg.

28 ~~60.~~ The modified release product of claim ~~56~~ 24 wherein the C_{max}, AUC_{inf} and AUC_{0-12} are approximately proportional to dosage strength.

29 ~~61.~~ The modified release product of claim ~~56~~ 24 or ~~57~~ 25 wherein the ratio of said first quantity of guaifenesin to said quantity of second quantity of guaifenesin is about 1:1 to about 1:5.

35

B

30 62. The modified release product of claim 29 wherein the ratio of said first quantity of guaifenesin to said quantity of second quantity of guaifenesin is about 1:5.

31 63. The modified release product of claim 27 wherein the C_{max} of said product is from about 1600 to 2500 μg/mL and said product has an AUC_{inf} of from about 5600 to 8750 hr*μg/mL.

32 64. The modified release product of claim 27 wherein the C_{max} of said product is at least 1900 μg/mL and said product has an AUC_{inf} of at least 7000 hr*μg/mL.

33 65. The modified release product of claim 26 wherein the C_{max} of said product is from about 800 to 1250 μg/mL and said product has an AUC_{inf} of from about 2800 to 4375 hr*μg/mL.

34 66. The modified release product of claim 26 wherein the C_{max} of said product is at least 1000 μg/mL and said product has an AUC_{inf} of at least 3500 hr*μg/mL.

35 67. The modified release product of claim 24 wherein said product has a half life, according to serum analysis, of at least three hours.

B5 cont.

36 68. The modified release product of claim 24 wherein said first and second portions each comprise abutting substantially planar layers which form a bilayer tablet.

37 69. The modified release product of claim 24 wherein said first portion is provided as a coating on said second portion.

38 70. The modified release product of claim 24 which is a capsule containing said first and second portions.

39 71. The modified release product of claim 24 which is approximately equally effective when administered to a patient on an empty or full stomach.

40 72. The modified release product of claim 27 which has the serum guaifenesin concentration profile of Figure 10.

41 73. A modified release product having two portions, wherein a first portion comprises a first quantity of guaifenesin in an immediate release form which becomes fully bioavailable in the subject's stomach and a second portion comprises a second quantity of guaifenesin in a sustained release form wherein the ratio of said first quantity to said second quantity is from about 1:1 to about 1:5 and the product provides a C_{max} in a human subject equivalent to the C_{max} obtained when the first of three doses of a standard immediate release formulation having one third the amount of guaifenesin is dosed every four hours over a 12 hour period and wherein said product also provides therapeutically effective bioavailability for at least twelve hours after a single dose in a human subject according to serum analysis.

36

B

42 74. The modified release product of claim 41 wherein the total quantity of guaifenesin is from about 600 mg to about 1200 mg.

43 75. The modified release product of claim 41 wherein the total quantity of guaifenesin is 600 mg.

44 76. The modified release product of claim 41 wherein the total quantity of guaifenesin is 1200 mg.

45 77. The modified release product of claim 41 wherein the C_{max}, AUC_{inf} and AUC_{0-12} are approximately proportional to dosage strength.

46 78. The modified release product of claim 41 wherein the ratio of said first quantity of guaifenesin to said quantity of second quantity of guaifenesin is about 1:5.

47 79. The modified release product of claim 44 wherein the C_{max} of said product is from about 1600 to 2500 μg/mL and said product has an AUC_{inf} of from about 5600 to 8750 hr*μg/mL.

B5 cancel

48 80. The modified release product of claim 44 wherein the C_{max} of said product is at least 1900 μg/mL and said product has an AUC_{inf} of at least 7000 hr*μg/mL.

49 81. The modified release product of claim 43 wherein the C_{max} of said product is from about 800 to 1250 μg/mL and said product has an AUC_{inf} of from about 2800 to 4375 hr*μg/mL.

50 82. The modified release product of claim 43 wherein the C_{max} of said product is at least 1000 μg/mL and said product has an AUC_{inf} of at least 3500 hr*μg/mL.

51 83. The modified release product of claim 41 wherein said product has a half life, according to serum analysis, of at least three hours.

52 84. The modified release product of claim 41 wherein said first and second portions each comprise abutting substantially planar layers which form a bilayer tablet.

53 85. The modified release product of claim 41 wherein said first portion is provided as a coating on said second portion.

54 86. The modified release product of claim 41 which is a capsule containing said first and second portions.

55 87. The modified release product of claim 41 which is approximately equally effective when administered to a patient on an empty or full stomach.

56 88. The modified release product of claim 44 which has the serum guaifenesin concentration profile of Figure 10.

37

B